XML 53 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Net (Loss) Income Per Share (Tables)
 9 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June 30, 2025 and 2024.
Three Months Ended June 30,Nine Months Ended June 30,
2025202420252024
(in thousands, except per share amounts)
Numerator:
Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.$(175,241)$(170,793)$22,119 $(428,957)
Denominator:
Weighted-average basic shares outstanding (1)
139,039 124,199 132,385 118,260 
Effect of dilutive securities— — 967 — 
Weighted-average diluted shares outstanding (1)
139,039 124,199 133,352 118,260 
Basic net (loss) income per share$(1.26)$(1.38)$0.17 $(3.63)
Diluted net (loss) income per share$(1.26)$(1.38)$0.17 $(3.63)
(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive.
Three Months Ended June 30,Nine Months Ended June 30,
2025202420252024
(in thousands)
Options768 753 756 711 
Restricted stock units5,178 3,976 4,770 4,060 
Total5,946 4,729 5,526 4,771